Financial Comparison: OptimizeRx (NASDAQ:OPRX) and SS&C Technologies (NASDAQ:SSNC)

SS&C Technologies (NASDAQ:SSNC) and OptimizeRx (NASDAQ:OPRX) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Insider & Institutional Ownership

96.9% of SS&C Technologies shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 16.4% of SS&C Technologies shares are held by company insiders. Comparatively, 5.6% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares SS&C Technologies and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SS&C Technologies	13.86%	19.92%	6.98%
OptimizeRx	-9.42%	4.50%	3.12%

Risk and Volatility

SS&C Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for SS&C Technologies and OptimizeRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS&C Technologies	0	2	6	1	2.89
OptimizeRx	1	2	7	1	2.73

SS&C Technologies presently has a consensus price target of $101.75, indicating a potential upside of 18.41%. OptimizeRx has a consensus price target of $16.88, indicating a potential upside of 7.55%. Given SS&C Technologies’ stronger consensus rating and higher probable upside, research analysts clearly believe SS&C Technologies is more favorable than OptimizeRx.

Valuation & Earnings

This table compares SS&C Technologies and OptimizeRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS&C Technologies	$6.15 billion	3.41	$760.50 million	$3.37	25.50
OptimizeRx	$109.51 million	2.67	-$18.66 million	N/A	N/A

SS&C Technologies has higher revenue and earnings than OptimizeRx.

Summary

SS&C Technologies beats OptimizeRx on 11 of the 12 factors compared between the two stocks.

About SS&C Technologies

SS&C Technologies Holdings, Inc. engages in the development and provision of software solutions to the financial services and healthcare industries. It operates through the following geographical segments: United States, Europe, Middle East and Africa, Asia Pacific and Japan, Canada, and the Americas, excluding the United States and Canada. Its products include advent genesis, antares, asset allocators, AWD, axys, BANC mall, BRIX, DST vision, evare, lightning, and moxy. The company was founded by William Charles Stone in March 1986 and is headquartered in Windsor, CT.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.